Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

Stephen J. Bagley; Shawn Kothari; Rifaquat Rahman; Eudocia Q. Lee; Gavin P. Dunn; Evanthia Galanis; Susan M. Chang; Louis Burt Nabors; Manmeet S. Ahluwalia; Roger Stupp; Minesh P. Mehta; David A. Reardon; Stuart A. Grossman; Erik P. Sulman; John H. Sampson; Simon Khagi; Michael Weller; Timothy F. Cloughesy; Patrick Y. Wen; Mustafa Khasraw

doi:10.1158/1078-0432.CCR-21-2750

Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

Stephen J. Bagley, Shawn Kothari, Rifaquat Rahman, Eudocia Q. Lee, Gavin P. Dunn, Evanthia Galanis, Susan M. Chang, Louis Burt Nabors, Manmeet S. Ahluwalia, Roger Stupp, Minesh P. Mehta, David A. Reardon, Stuart A. Grossman, Erik P. Sulman, John H. Sampson, Simon Khagi, Michael Weller, Timothy F. Cloughesy, Patrick Y. Wen, Mustafa Khasraw

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of glioblastoma clinical trials. Here, we review the literature, identify challenges related to clinical trial eligibility criteria and trial design in glioblastoma, and provide recommendations from the Think Tank. In addition, we provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on ClinicalTrials.gov as “recruiting” or “not yet recruiting” as of February 2021.

Original language	English (US)
Pages (from-to)	594-602
Number of pages	9
Journal	Clinical Cancer Research
Volume	28
Issue number	4
DOIs	https://doi.org/10.1158/1078-0432.CCR-21-2750
State	Published - Feb 15 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1158/1078-0432.CCR-21-2750

Cite this

Bagley, S. J., Kothari, S., Rahman, R., Lee, E. Q., Dunn, G. P., Galanis, E., Chang, S. M., Nabors, L. B., Ahluwalia, M. S., Stupp, R., Mehta, M. P., Reardon, D. A., Grossman, S. A., Sulman, E. P., Sampson, J. H., Khagi, S., Weller, M., Cloughesy, T. F., Wen, P. Y., & Khasraw, M. (2022). Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research, 28(4), 594-602. https://doi.org/10.1158/1078-0432.CCR-21-2750

Bagley, SJ, Kothari, S, Rahman, R, Lee, EQ, Dunn, GP, Galanis, E, Chang, SM, Nabors, LB, Ahluwalia, MS, Stupp, R, Mehta, MP, Reardon, DA, Grossman, SA, Sulman, EP, Sampson, JH, Khagi, S, Weller, M, Cloughesy, TF, Wen, PY & Khasraw, M 2022, 'Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement', Clinical Cancer Research, vol. 28, no. 4, pp. 594-602. https://doi.org/10.1158/1078-0432.CCR-21-2750

@article{d783066d0a714792bba042bb06a43735,

title = "Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement",

abstract = "Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of glioblastoma clinical trials. Here, we review the literature, identify challenges related to clinical trial eligibility criteria and trial design in glioblastoma, and provide recommendations from the Think Tank. In addition, we provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on ClinicalTrials.gov as “recruiting” or “not yet recruiting” as of February 2021.",

author = "Bagley, {Stephen J.} and Shawn Kothari and Rifaquat Rahman and Lee, {Eudocia Q.} and Dunn, {Gavin P.} and Evanthia Galanis and Chang, {Susan M.} and Nabors, {Louis Burt} and Ahluwalia, {Manmeet S.} and Roger Stupp and Mehta, {Minesh P.} and Reardon, {David A.} and Grossman, {Stuart A.} and Sulman, {Erik P.} and Sampson, {John H.} and Simon Khagi and Michael Weller and Cloughesy, {Timothy F.} and Wen, {Patrick Y.} and Mustafa Khasraw",

note = "Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research",

year = "2022",

month = feb,

day = "15",

doi = "10.1158/1078-0432.CCR-21-2750",

language = "English (US)",

volume = "28",

pages = "594--602",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "4",

}

TY - JOUR

T1 - Glioblastoma Clinical Trials

T2 - Current Landscape and Opportunities for Improvement

AU - Bagley, Stephen J.

AU - Kothari, Shawn

AU - Rahman, Rifaquat

AU - Lee, Eudocia Q.

AU - Dunn, Gavin P.

AU - Galanis, Evanthia

AU - Chang, Susan M.

AU - Nabors, Louis Burt

AU - Ahluwalia, Manmeet S.

AU - Stupp, Roger

AU - Mehta, Minesh P.

AU - Reardon, David A.

AU - Grossman, Stuart A.

AU - Sulman, Erik P.

AU - Sampson, John H.

AU - Khagi, Simon

AU - Weller, Michael

AU - Cloughesy, Timothy F.

AU - Wen, Patrick Y.

AU - Khasraw, Mustafa

PY - 2022/2/15

Y1 - 2022/2/15

N2 - Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of glioblastoma clinical trials. Here, we review the literature, identify challenges related to clinical trial eligibility criteria and trial design in glioblastoma, and provide recommendations from the Think Tank. In addition, we provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on ClinicalTrials.gov as “recruiting” or “not yet recruiting” as of February 2021.

AB - Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of glioblastoma clinical trials. Here, we review the literature, identify challenges related to clinical trial eligibility criteria and trial design in glioblastoma, and provide recommendations from the Think Tank. In addition, we provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on ClinicalTrials.gov as “recruiting” or “not yet recruiting” as of February 2021.

UR - http://www.scopus.com/inward/record.url?scp=85118566876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118566876&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-21-2750

DO - 10.1158/1078-0432.CCR-21-2750

M3 - Review article

C2 - 34561269

AN - SCOPUS:85118566876

SN - 1078-0432

VL - 28

SP - 594

EP - 602

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 4

ER -

Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this